Gopten Mite (Trandolapril)

Gopten Mite is indicated for the management of several cardiovascular conditions where reduction of blood pressure or cardiac workload is desired.

• Hypertension (high blood pressure) as monotherapy or in combination with other antihypertensives.
• Heart failure, particularly in patients with reduced ejection fraction, to improve symptoms and outcomes.
• Post‑myocardial infarction therapy to reduce the risk of subsequent cardiovascular events.
• Diabetic nephropathy, as part of a regimen to slow progression of kidney disease.
• High‑risk patients with left ventricular dysfunction to prevent remodeling.

The safety profile of trandolapril includes both frequently observed effects and less common but potentially serious reactions.

Common

• Persistent dry cough, which may develop weeks after therapy initiation.
• Dizziness or light‑headedness, particularly upon standing, due to blood pressure lowering.
• Headache that is mild to moderate in intensity.
• Fatigue or general weakness, often improving with continued use.

Serious

• Angioedema, presenting as rapid swelling of the face, lips, tongue, or throat and requiring immediate medical attention.
• Severe hypotension, which can cause fainting, shock, or organ hypoperfusion.
• Acute kidney injury, indicated by a sudden increase in serum creatinine or reduced urine output.

Before starting Gopten Mite, clinicians should evaluate several patient‑specific factors to minimize risks and ensure appropriate use.

• Pregnancy: Trandolapril is classified as category D; it should be avoided in pregnancy due to potential fetal toxicity.
• Renal impairment: Dose adjustment may be required in patients with reduced kidney function.
• Hyperkalemia: Monitor serum potassium levels, especially when combined with potassium‑sparing diuretics or supplements.
• History of angioedema: Patients with prior angioedema related to ACE inhibitors should not receive trandolapril.
• Concomitant use of NSAIDs: May diminish antihypertensive effect and increase risk of renal dysfunction.
• Elderly patients: Start at lower doses and monitor for hypotension and renal changes.

Trandolapril can interact with other medicines, altering its effectiveness or increasing the likelihood of adverse effects.

Avoid

• Potassium‑rich supplements or potassium‑sparing diuretics, which can precipitate dangerous hyperkalemia.
• Aliskiren in patients with diabetes or renal impairment, due to increased risk of renal dysfunction and hypotension.
• Direct renin inhibitors combined with ACE inhibitors, which is generally contraindicated.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs), which may reduce blood‑pressure control and affect kidney function.
• Diuretics, especially loop or thiazide types, as they can enhance the initial hypotensive effect.
• Lithium, because ACE inhibitors may increase lithium concentrations and risk of toxicity.